[1] Malmstrom RE. Pharmacology of neuropeptide Y receptor antagonists.Focus on cardiovascular functions
[J]. Eur J Pharmacol, 2002, 447(1):11-30.

[2]  刘培党,晋光荣,王鹤鸣,等.大鼠颈上交感神经节的形态学研究
[J].徐州医学院学报,2000,20(1):36-38.

[3] Hashimoto R, Udagawa J, Kagohashi Y. Direct and indirect effects of neuropeptide Y and neurotrophin 3 on myelination in the neonatal brains
[J]. Brain Res, 2011, 1373(1):55-66.

[4] Montecucco F, Pende A, Quercioli A. Inflammation in the pathophysiology of essential hypertension
[J].J Nephrol, 2011, 24(1):23-34.

[5] Grassi G. Sympathetic neural activity in hypertension and related diseases
[J].Am J Hypertens, 2010, 23(10):1052-1060.

[6] Alves FH, Crestani CC, Resstel LB. Cardiovascular effects of noradrenaline microinjected into the insular cortex of unanesthetized rats
[J]. Auton Neurosci, 2011,160(1-2):90-98.

[7] Dorn GW 2nd. Adrenergic signaling polymorphisms and their impact on cardiovascular disease
[J].Physiol Rev, 2010, 90(3):1013-1062.

[8] Zhao XH, Sun XY, Edvinsson L. Does the neuropeptide Y Y1 receptor contribute to blood pressure control in the spontaneously hypertensive rat
[J]. J Hypertens, 1997, 15(1):19-27.

[9] Kuo LE, Abe K, Zukowska Z. Stress, NPY and vascular remodeling: Implications for stress-related diseases
[J].Peptides, 2007, 28(2):435-440.